Objective Although the serum C-reactive protein (CRP) level may, to some extent, predict the disease activity in patients with Crohn's disease (CD), it is not always elevated during periods of disease activity. This study aimed to identify factors predicting the presence of active intestinal lesions in CD patients without an elevated CRP level. Methods CD patients in whom the presence or absence of active intestinal lesions was evaluated using endoscopic and/or radiologic modalities were divided into two groups based on a negative (<3 mg/L) or positive (! 3 mg/L) CRP level. The correlations between the presence of active intestinal lesions and various clinical variables, including the Crohn's Disease Activity Index (CDAI), leukocyte and platelet counts and hemoglobin, serum albumin and CRP levels, were determined in the CRP-negative patients. Results Of the 128 patients examined, 70 had a negative CRP status, approximately half of whom had active intestinal lesions. The multivariate analysis revealed a CDAI of >100 and platelet count of >33×10 4 /μL to be significant predictive factors for the presence of active lesions in the CRP-negative patients [CDAI >100, odds ratio (OR) =5.55; 95% confidence interval (CI), 1.80-18.74, platelet count >33×10 4 /μL, OR =5.94; 95% CI, 1.34-28.87]. The sensitivity of fulfillment of either criterion for the presence of active intestinal lesions was 83%, while the specificity of fulfillment of both criteria was 94%. Conclusion A relatively low CDAI and platelet count were identified as predictive markers of the presence of active intestinal lesions in CRP-negative CD patients. These results suggest that symptoms and laboratory data should be evaluated very carefully in such patients.
Introduction
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract, characterized by progression from a primarily inflammatory disease to stricture or penetration associated with the occurrence of complications, in-Current opinions increasingly cite the need to achieve both a clinical response and mucosal healing for the treatment of CD. Mucosal healing is associated with sustained clinical remission and a longer time to relapse (4, 5) as well as reduced rates of hospitalization and surgery (4, 6, 7) . In this regard, the concept of mucosal healing in the setting of CD has changed, as inflammation in CD patients is not confined to the mucosa, but rather involves the entire thickness of the intestinal wall. Therefore, transmural healing, i.e., the disappearance of active intestinal lesions, is regarded as an important therapeutic goal in the treatment of patients with CD. Based on this background, the appropriate evaluation of the presence or absence of active intestinal lesions is required to improve the outcomes of CD patients.
However, assessing the presence or absence of active intestinal lesions in patients with CD is often difficult because CD may involve the entire gastrointestinal system, particularly the small bowel. In general, endoscopy, including ileocolonoscopy, capsule endoscopy and balloon enteroscopy, and/or radiologic modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) and fluoroscopy, are needed to evaluate the presence or absence of active lesions. In addition, repeated examinations with these modalities are required during a prolonged disease course. Therefore, determining the state of intestinal activity is burdensome for patients, both physically and economically, and identification of surrogate markers of the presence of active intestinal lesions that can be evaluated easily, noninvasively and economically to replace imaging techniques is thus desirable.
The serum C-reactive protein (CRP) level is a candidate for this purpose. CRP is an acute-phase protein that is produced and released by hepatocytes following triggering by cytokines, including interleukin (IL)-6, IL-1 and tumor necrosis factor (TNF)-α. In the clinical setting of CD, measuring the CRP level enables the identification of 70-100% of newly developed, active CD patients (8) ; therefore, this parameter may constitute a valuable marker for predicting active intestinal disease. In this context, several reports have investigated the correlation between the CRP level and the mucosal or disease status of CD, showing the ability of CRP to predict the presence of active disease with 48-68% sensitivity and 58-91% specificity (9, 10) . However, it has also been reported that the CRP level is not elevated in 20-25% of CD patients, despite the presence of disease and mucosal activity (11) . In another study, approximately one-third of CD patients with clinically active disease had a normal CRP level (12) . Hence, an elevated CRP level can be used to predict, to some extent, the presence of active intestinal lesions, although a negative CRP level does not always indicate the absence of active lesions. In the clinical setting, it is critical to identify CD patients with active intestinal lesions among those without an elevated CRP level.
In this study, we therefore sought to identify the factors predictive of the presence of active intestinal lesions in CD patients without an elevated serum CRP level using clinical parameters and various blood test results.
Materials and Methods

Patients and study design
Ambulatory CD patients who visited Okayama University Hospital periodically and in whom the presence or absence of active intestinal lesions was evaluated using endoscopic and/or radiologic modalities between January 2006 and September 2012 were considered eligible for this study. All of the patients had an established diagnosis of CD based on standard clinical, endoscopic, histological and radiographic criteria (13) . Patients with active infection, abdominal or perianal abscesses, or intestinal obstruction were excluded from the study.
The correlations between the presence or absence of active intestinal lesions, evaluated using endoscopy and/or radiology, and clinical symptoms as well as the results of hematological examinations, including the white blood cell (WBC) and platelet (PLT) counts and hemoglobin, serum albumin and CRP levels, were determined. We divided the patients into two groups according to the serum CRP level. The positive CRP group included patients with a CRP level of ! 3 mg/L, while the negative CRP group comprised patients with a CRP level of <3 mg/L. The clinical disease activity of the patients was evaluated using the Crohn's Disease Activity Index (CDAI) (14) . The patients' demographic, historical and medical data were obtained from their medical charts.
The study protocol was approved by the institutional review board of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. Informed consent was obtained from each patient.
Evaluation of intestinal lesions
In all enrolled patients, we evaluated the mucosal status of the colon and terminal ileum using ileocolonoscopy. In cases involving locations proximal to the terminal ileum, the presence or absence of active lesions was determined via balloon enteroscopy and/or radiologic modalities, including CT and fluoroscopy, if no active lesions were observed on ileocolonoscopy. The endoscopic mucosal status was assessed based on the presence of ulcers and areas of erosion. The presence of active lesions was defined as any finding of deep, superficial or aphthoid ulceration. On small bowel fluoroscopy, active lesions were defined as the presence of any area of ulceration or erosion, according to the findings of the double-contrast method. On CT, intravenous contrast medium was used to provide positive or negative contrast between the bowel lumen and surrounding structures. The presence of mucosal enhancement, wall thickness, engorgement of the vasa recta (comb sign) or adenopathy on CT was defined as indicating active lesions (15, 16) . 
Statistical analysis
The statistical analysis was carried out using the JMP software program (version 9, SAS Institute, Cary, USA).
Comparative models, such as the chi-square test and MannWhitney test, were used for the cross-sectional analysis of categorical data. In order to identify factors predictive of the presence of active lesions, univariate and multivariate analyses were performed using a logistic regression model with corresponding calculations of odds ratios (ORs) and 95% confidence intervals (CIs). A receiver operating characteristic (ROC) curve analysis was used to determine the appropriate cutoff values for CDAI, WBC, PLT, hemoglobin, serum albumin and CRP. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio and negative likelihood ratio with 95% CI for predicting the presence of active lesions were determined based on statistically significant parameters. All p values were two-sided and considered to be significant when less than 0.05.
Results
Clinical characteristics of the patients
A total of 128 CD patients fulfilled the criteria detailed in the methods section ( Table 1 ). The procedures used to evaluate the mucosal status are shown in Table 2 . Of the 128 patients, 58 were classified into the positive (! 3 mg/L) CRP group and 70 were classified into the negative (<3 mg/ L) CRP group. The patients in the negative CRP group had significantly lower CDAI values (median, 101; interquartile range (IQR), 72-151) than those in the positive CRP group (median, 171; IQR, 145-209) (p<0.0001). Active intestinal lesions were observed in 86% of the positive CRP patients and in approximately half of the negative CRP patients. The hematological examinations revealed significantly higher CRP, WBC and PLT levels in the patients in the positive CRP group than in the negative CRP group (13.0 mg/L vs. 0.8 mg/L, p<0.0001, 6,760/μL vs. 5,290/μL, p=0.0007 and 35.3×10
4 /μL vs. 27.7×10 4 /μL, p=0.0021, respectively). In ad- dition, the serum albumin levels were significantly lower in the patients in the positive CRP group than in the negative CRP group (3.6 g/dL vs. 4.2 g/dL, p<0.001).
Correlations between the presence of active intestinal lesions and the clinical variables in the negative CRP group
Approximately 50% of the negative CRP patients had active intestinal lesions. In the clinical setting, therefore, the identification of factors predictive of the presence of active lesions is required to evaluate negative CRP patients. Table 3 shows the correlations between the presence of active intestinal lesions and the clinical variables, including patient characteristics, CDAI values and hematological results in the negative CRP group. The patients with active intestinal lesions had significantly higher CDAI and PLT values than those without active lesions (135 vs. 88, p<0.0001, and 32.5×10 4 /μL vs. 25.3×10 4 /μL, p=0.0063, respectively). Therefore, in the negative CRP group, there were differences in symptoms and hematological results between the patients with and without active intestinal lesions.
Subanalyses of the negative CRP group
Because there was heterogeneity among our patients regarding the purpose of the intestinal examinations, the presence or absence of prior surgery and the location and severity of active lesions, an analysis was performed among the patients subdivided according to each factor. Although all subanalyses showed similar results to those of the analysis including all patients, statistical significance was observed in limited analyses due to the decrease in the number of patients.
In the analysis of the patients subdivided according to the purpose of the examinations, the PLT values alone were significantly higher in the patients with active lesions among those who had undergone intestinal examinations due to the exacerbation of symptoms (p=0.014) or to confirm remission (p=0.026). Although the PLT values did not exhibit statistically significant differences between the patients with and without active lesions in the subanalysis of patients without prior surgery, both the CDAI and PLT values retained their statistical significance in the patients with a history of prior surgery (p=0.0034 and p=0.0061, respectively). In addition, both the CDAI and PLT values could be used to discriminate patients with active lesions in the small intestine alone from those without active lesions throughout ileum and colon (110 vs. 88, p=0.0037 and 33.5×10 4 /μL vs. 25.4×10 4 /μL, p=0.013, respectively).
Because aphthous lesions could not be accurately evaluated using the radiologic modalities, an analysis of subjects excluding those with aphthous lesions alone was also performed. In this analysis, both the PLT and CDAI values showed significant differences between the patients with and without active 'ulcerative' lesions (p=0.018 and p<0.0001, respectively). In contrast, no parameters differed significantly between the subjects with and without aphthous lesions alone. 
Factors predictive of the presence of active lesions in the negative CRP group
Univariate and multivariate analyses of the factors predicting the presence of active intestinal lesions in the negative CRP patients were conducted using the CDAI values and hematological variables ( Table 4 ). The cutoff values were determined according to a ROC curve analysis to discriminate patients with active intestinal lesions from those without active lesions. Factors associated with the presence of active intestinal lesions identified in the univariate analysis were a CDAI of >100, CRP level of >1.4 mg/L, hemoglobin level of <13.8 g/dL, PLT count of >33×10 4 /μL and serum albumin level of <3.6 g/dL. Furthermore, the multivariate analysis revealed a CDAI of >100 and PLT count of >33× 10 4 /μL to be independent factors predictive of the presence of active lesions in the negative CRP patients (CDAI >100, OR =5.55; 95% CI, 1.80-18.74, PLT >33×10 4 /μL, OR = 5.94; 95% CI, 1.34-28.87, respectively).
Sensitivity, specificity and predictive value of CDAI and PLT for the presence of active lesions in the negative CRP group
Because two criteria, namely, CDAI >100 and PLT >33× 10 4 /μL, were identified as candidate predictive surrogate markers of the presence of active intestinal lesions in the negative CRP patients, the sensitivity, specificity, PPV, NPV, positive likelihood ratio, negative likelihood ratio and accuracy of each of these criteria were evaluated ( Table 5 ). The predictive value of CDAI >100 was quite high (all values were more than 70%). In contrast, when the cutoff of CDAI was set at >150, the sensitivity was only 44%. Among 18 patients with a CDAI between 100 and 150, 11 (61%) had active lesions. A PLT count of >33×10 4 /μL was not found to be sensitive for predicting the presence of active disease, although the specificity was 85%, suggesting that the PLT values of the patients without active lesions were likely to be below 33×10 4 /μL. The predictive value of the combination of CDAI >100 and PLT >33×10 4 /μL was also determined. The specificity of fulfillment of both criteria in predicting the presence of active intestinal lesions was 0.94 (95% CI, 0.85-0.98), indicating that patients without active lesions rarely presented with both a CDAI of >100 and PLT count of >33×10 4 /μL. Furthermore, the negative CRP patients presenting with either of these criteria had active lesions, with a sensitivity of 0.83 (95% CI, 0.73-0.91), specificity of 0.65 (95% CI, 0.53-0.73) and accuracy of 0.74 (95% CI, 0.63-0.82). These results suggest that the presence of active intestinal lesions can be predicted noninvasively in CRP-negative CD patients using the CDAI and PLT count.
Discussion
In the present study, we evaluated noninvasive predictive markers of the presence of active intestinal lesions in CD patients without an elevated serum CRP level and showed the CDAI and PLT to be such candidates. Although the appropriate cutoff value for the CDAI to discriminate active from quiescent disease is considered to be 150, our findings indicate that this value should be 100 in CRP-negative CD patients with regard to the presence of active lesions in the intestines. Furthermore, the addition of the PLT count to the CDAI facilitated the identification of truly inactive patients (those who had no active intestinal lesions) among the CRPnegative CD patients.
Mucosal healing in CD patients is associated with prolonged clinical remission and a longer time to relapse (4, 5) , as well as with reductions in hospitalization and surgery (4, 6, 7), compared to that observed in subjects with active intestinal inflammation. In a 2009 study of the longterm outcomes of CD patients treated with infliximab, those who had achieved complete or partial mucosal healing on follow-up endoscopy had a statistically significantly lower rate of major abdominal surgery (14.1%) than those who did not exhibit mucosal healing (38.4%) (7) . In addition to a lower surgical resection rate, 42.2% of the patients with mucosal healing required hospitalization after a median followup of 68.7 months, compared to 59.3% of those without mucosal healing (7). This trend was also noted in a subgroup of the ACCENT I study population (4). Therefore, mucosal healing is an increasingly important therapeutic goal in the treatment of patients with CD (17, 18) , and appropriately evaluating the mucosal status is required.
Recently, the concept of transmural healing was introduced, as inflammation is not confined to the intestinal mucosa in the setting of CD (19) . CD patients with mucosal healing may not always achieve transmural healing. Although its precise definition has not been established, transmural healing is consistent with the complete disappearance of active intestinal lesions. In this regard, assessing the presence or absence of active intestinal lesions is increasingly important in the clinical setting. However, evaluating intestinal inflammation is rather difficult in patients with CD because the disease can affect the entire gastrointestinal system, particularly the small intestine, in areas beyond the reach of ileocolonoscopy. In addition, performing radiologic examinations and/or ileocolonoscopy to confirm the status of intestinal activity is burdensome to the patient, both physically and economically. In particular, the effects of ionizing irradiation may be problematic, as repeated evaluations are required in cases involving a long-term disease duration.
Against this background, several noninvasive surrogate markers have been suggested. In particular, the identification of blood or fecal markers would be ideal if sufficiently predictive. In this context, the CRP level is considered to be one of the most promising noninvasive markers. The CRP level is widely used to evaluate the disease activity in patients with CD because it shows an acceptable correlation with the disease as well as endoscopic and histological activity (20) . However, no clear cutoff values to discriminate active from quiescent disease have been established. In the present study, we defined the cutoff of CRP as 3 mg/L, because this value is the lowest among studies that have evaluated the correlation between the CRP level and CD status (11, 20) and because the ROC curve analysis demonstrated the appropriate cutoff level for CRP to detect active lesions to be 3.4 mg/L. As the majority of patients with a positive (! 3 mg/L) CRP status have active intestinal lesions, their intestines should be examined carefully. In this regard, our aim of identifying surrogate markers predicting the presence of active intestinal lesions in CRP-negative CD patients is critical for providing appropriate treatment for these patients. A CDAI of >100 and PLT count of >33×10 4 /μL are novel criteria for identifying CRP-negative CD patients who require more intensive treatment.
In this study, the PLT count was identified as a factor predictive of the presence of active lesions in CD patients without an elevated serum CRP level. Many clinicians engaged in treating patients with inflammatory bowel disease (IBD) have reported platelet elevation in IBD patients with clinical activity. In fact, Kapsoritakis et al. carried out hematological examinations of CD patients with and without activity and healthy controls and found that the mean PLT value was higher in the patients with active disease than in the inactive CD patients or healthy controls (21) . In addition, recent studies have shown the PLT count to be an indicator of active inflammation in CD patients treated with anti-TNF-α antibodies (22, 23) . Therefore, to some extent, the PLT count is regarded to be a biomarker reflective of active inflammation in IBD patients, although the correlation with mucosal status and/or presence of active intestinal lesions has scarcely been reported. Our findings of the value of the combination of CDAI and PLT values in negative CRP patients highlight the potential of the PLT count as a noninvasive predictive marker of the presence of disease activity of clinical importance.
We determined the cutoff values of CDAI and PLT for predicting the presence of active intestinal lesions to be > 100 and >33×10 4 /μL, respectively. The specificity of fulfillment of both criteria for the presence of active lesions was 94%, although the sensitivity was rather low. The fulfillment of either criterion predicted the presence of active lesions with 83% sensitivity and 65% specificity. In the clinical setting, CD patients who satisfy both criteria may not need to undergo endoscopy and/or imaging studies, whereas those who fulfill only one or none of these criteria should be followed up meticulously and treated with appropriate endoscopic and/or radiologic examinations in cases lacking recent imaging analyses and/or involving a recent shift to positivity for either criterion.
Due to their noninvasiveness, fecal markers, such as fecal calprotectin, are also candidates as markers of the presence of active lesions. Previous reports have indicated that the fecal calprotectin level can be used to predict active inflammation in CD patients with 89-91% sensitivity and 44-58% specificity (9, 10) . As a new approach using the feces of IBD patients, we recently investigated and reported the performance of a fecal immunochemical test (FIT), a widely used screening modality for colorectal cancer, for the evaluation of the mucosal status in UC patients (24) . Exploring the ability of FIT to indicate the mucosal status in the setting of CD is a further challenge.
There are some limitations associated with this study attributable to its retrospective nature. In particular, the heterogeneity of the study population regarding the purpose of the evaluation of intestinal lesions, presence or absence of prior surgery and location and severity of active lesions may have affected the results. However, the analyses of the patients subdivided according to such factors showed similar results, although statistical significance was not observed in all subanalyses due to the decrease in the patient number. This study also has an inevitable limitation regarding the modalities used to evaluate the presence or absence of active lesions in the small intestine. Endoscopically evaluating the entire intestine in order to precisely detect active lesions is desirable, as patients with endoscopic activity in the intestinal mucosa are inevitably included among those with the presence of active lesions. However, because previous studies have shown that CT can be used to detect active intestinal lesions with high sensitivity (16, 25) , our results should not be affected by significant bias.
In conclusion, the present study demonstrated that the presence of active intestinal lesions in CRP-negative CD patients can be predicted using the CDAI and PLT count. Because CD patients without CRP elevation are the most difficult to evaluate with respect to the mucosal and disease activity, our findings may be helpful for the clinical treatment of such patients. Moreover, the physical and economic burden on these patients can be reduced by applying markers that make various endoscopic and/or radiologic examinations redundant.
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